Michel Scotté
Research Subjects
Michel Scotté has a total of 638 co-authors. Here are the top co-authors by number of shared publications:
F Michot
29 shared publicationsMaryvonne Daveau
17 shared publicationsP Ténière
Department of digestive tract surgery, IFR23-University Hospital of Rouen, Rouen, France
15 shared publicationsMartine Hiron
14 shared publicationsP Tenière
13 shared publicationsI Leblanc
12 shared publications
Latest Publications
- 3 May 2017
- Published by Bioscientifica in Endocrine Abstracts
Three year prospective study in morbidly obese patients between longitudinal gastrectomy and gastric bypass based on a composite outcome combining weight loss efficacy and surgery related complications (PHRC SLEEVE K060213 / IDRCB2007-A00373-50)
Since its first description in 2000, Longitudinal Gastrectomy (LG) has become the first surgical procedure in the treatment of morbid obesity in the world, exceeding in numbers Gastric Bypass (GB). GB is considered to have better results regarding long-term weight loss and improvement in co-morbidities. We aimed to demonstrate that LG is non inferior to GB for a composite end point that included more than 50% excess weight loss from the baseline and surgery related complications after a mean follow-up of 36 months. This is a prospective study in morbidly obese patients that tested a two hypotheses composite outcome: the first hypothesis was that after 36 months LG was non-inferior to GB regarding EWL (the predefined margin of non-inferiority was ±15%), and the second hypothesis was the presence of significant difference in post-operative morbidity and mortality. From February 2008 to March 2015 we included 277 patients (91 GB vs 186 LG). The mean age was 41.1 years, 19.2% had a previous bariatric operation, 85.9% were women and the average pre-intervention BMI was 45.3 kg/m2. At baseline there were no significant differences between the GB and LG for age, sex and BMI. The % of patients with EWL > 50% was at 18 months for 82.1% (GB) vs 84.5% (LG), and 79.1 vs. 79.5% respectively at 36 months. The estimated difference in EWL was [−10.5% to 9.8%], confirming the non-inferiority of LG compared to BP. Finally there was a significant less morbidity and mortality for the LG group (GB vs LG, 12.1 vs. 4.8%, one death for LG, P=0.01). This is the first prospective study demonstrating that LG is not inferior to GB for an estimated 10% difference in EWL but with less surgical complications. These results reinforce the choice of LG as surgical procedure for obesity.
- 3 May 2017
- Published by Bioscientifica in Endocrine Abstracts
Three year prospective study in morbidly obese patients between longitudinal gastrectomy and gastric bypass based on a composite outcome combining weight loss efficacy and surgery related complications (PHRC SLEEVE K060213 / IDRCB2007-A00373-50)
Since its first description in 2000, Longitudinal Gastrectomy (LG) has become the first surgical procedure in the treatment of morbid obesity in the world, exceeding in numbers Gastric Bypass (GB). GB is considered to have better results regarding long-term weight loss and improvement in co-morbidities. We aimed to demonstrate that LG is non inferior to GB for a composite end point that included more than 50% excess weight loss from the baseline and surgery related complications after a mean follow-up of 36 months. This is a prospective study in morbidly obese patients that tested a two hypotheses composite outcome: the first hypothesis was that after 36 months LG was non-inferior to GB regarding EWL (the predefined margin of non-inferiority was ±15%), and the second hypothesis was the presence of significant difference in post-operative morbidity and mortality. From February 2008 to March 2015 we included 277 patients (91 GB vs 186 LG). The mean age was 41.1 years, 19.2% had a previous bariatric operation, 85.9% were women and the average pre-intervention BMI was 45.3 kg/m2. At baseline there were no significant differences between the GB and LG for age, sex and BMI. The % of patients with EWL > 50% was at 18 months for 82.1% (GB) vs 84.5% (LG), and 79.1 vs. 79.5% respectively at 36 months. The estimated difference in EWL was [−10.5% to 9.8%], confirming the non-inferiority of LG compared to BP. Finally there was a significant less morbidity and mortality for the LG group (GB vs LG, 12.1 vs. 4.8%, one death for LG, P=0.01). This is the first prospective study demonstrating that LG is not inferior to GB for an estimated 10% difference in EWL but with less surgical complications. These results reinforce the choice of LG as surgical procedure for obesity.
- Open Access
- 29 January 2017
- Published by Wiley in Journal of Obesity
- Vol. 2017, 1-7
Excess Body Mass Index Loss at 3 Months: A Predictive Factor of Long-Term Result after Sleeve Gastrectomy
Introduction.Laparoscopic Sleeve Gastrectomy (SG) is considered as successful if the percentage of Excess Body Mass Index Loss (% EBMIL) remains constant over 50% with long-term follow-up. The aim of this study was to evaluate whether early % EBMIL was predictive of success after SG.Methods.This retrospective study included patients who had SG with two years of follow-up. Patients had follow-up appointments at 3 (M3), 6, 12, and 24 months (M24). Data as weight and Body Mass Index (BMI) were collected systematically. We estimated the % EBMIL necessary to establish a correlation between M3 and M24 compared to % EBMIL speeds and calculated a limit value of % EBMIL predictive of success.Results.Data at operative time, M3, and M24 were available for 128 patients. Pearson test showed a correlation between % EBMIL at M3 and that at M24 (). % EBMIL speed between surgery and M3 () was significant but not between M3 and M24. A linear regression analysis proved that % EBMIL over 20.1% at M3 () predicted a final % EBMIL over 50%.Conclusions.% EBMIL at M3 after SG is correlated with % EBMIL in the long term. % EBMIL speed was significant in the first 3 months. % EBMIL over 20.1% at M3 leads to the success of SG.- 29 January 2017
- Published by Wiley in Journal of Obesity
- Vol. 2017, 1-7
Open AccessExcess Body Mass Index Loss at 3 Months: A Predictive Factor of Long-Term Result after Sleeve Gastrectomy
Introduction.Laparoscopic Sleeve Gastrectomy (SG) is considered as successful if the percentage of Excess Body Mass Index Loss (% EBMIL) remains constant over 50% with long-term follow-up. The aim of this study was to evaluate whether early % EBMIL was predictive of success after SG.Methods.This retrospective study included patients who had SG with two years of follow-up. Patients had follow-up appointments at 3 (M3), 6, 12, and 24 months (M24). Data as weight and Body Mass Index (BMI) were collected systematically. We estimated the % EBMIL necessary to establish a correlation between M3 and M24 compared to % EBMIL speeds and calculated a limit value of % EBMIL predictive of success.Results.Data at operative time, M3, and M24 were available for 128 patients. Pearson test showed a correlation between % EBMIL at M3 and that at M24 (). % EBMIL speed between surgery and M3 () was significant but not between M3 and M24. A linear regression analysis proved that % EBMIL over 20.1% at M3 () predicted a final % EBMIL over 50%.Conclusions.% EBMIL at M3 after SG is correlated with % EBMIL in the long term. % EBMIL speed was significant in the first 3 months. % EBMIL over 20.1% at M3 leads to the success of SG. - 20 April 2016
- Published by Wiley in World Journal of Surgery
- Vol. 40 (8) , 1941-1950
Adjuvant I‐131 Lipiodol After Resection or Radiofrequency Ablation for Hepatocellular Carcinoma
Background and objectives: High rates of recurrence have been observed after curative treatment for hepatocellular carcinoma (HCC). The main aim of this study was to establish the influence of adjuvant transarterial radioembolization‐based I‐131 lipiodol on survival and recurrence.Methods: Between 2004 and 2010, 38 patients were treated with adjuvant I‐131 lipiodol therapy, at a dosage of 2220 MBq, within 4 months after surgery. This treated cohort was compared to a control cohort consisting of 42 consecutive patients operated prior to the time the I‐131 lipiodol treatment became available.Results: Recurrence‐free survival in the control and in the I‐131 lipiodol cohort was 12.6 and 18.7 months, respectively (HR = 1.871, p = 0.025). At 2 and 5 years, the cumulative incidence of a first recurrence or death was, respectively, 50 % and 61 % in the treated cohort versus 69 % and 74 % in the control cohort. Median overall survival was 55 and 29 months, respectively (p = 0.051). Among patients with a recurrence at 2 years, more patients had already experienced such recurrence at 1 year in the control cohort (70 % vs 33 %, p = 0.014).Conclusions: Adjuvant I‐131 lipiodol improves disease‐free survival in patients with HCC.
- 20 April 2016
- Published by Wiley in World Journal of Surgery
- Vol. 40 (8) , 1941-1950
Adjuvant I‐131 Lipiodol After Resection or Radiofrequency Ablation for Hepatocellular Carcinoma
Background and objectives: High rates of recurrence have been observed after curative treatment for hepatocellular carcinoma (HCC). The main aim of this study was to establish the influence of adjuvant transarterial radioembolization‐based I‐131 lipiodol on survival and recurrence.Methods: Between 2004 and 2010, 38 patients were treated with adjuvant I‐131 lipiodol therapy, at a dosage of 2220 MBq, within 4 months after surgery. This treated cohort was compared to a control cohort consisting of 42 consecutive patients operated prior to the time the I‐131 lipiodol treatment became available.Results: Recurrence‐free survival in the control and in the I‐131 lipiodol cohort was 12.6 and 18.7 months, respectively (HR = 1.871, p = 0.025). At 2 and 5 years, the cumulative incidence of a first recurrence or death was, respectively, 50 % and 61 % in the treated cohort versus 69 % and 74 % in the control cohort. Median overall survival was 55 and 29 months, respectively (p = 0.051). Among patients with a recurrence at 2 years, more patients had already experienced such recurrence at 1 year in the control cohort (70 % vs 33 %, p = 0.014).Conclusions: Adjuvant I‐131 lipiodol improves disease‐free survival in patients with HCC.
- 6 May 2015
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 63 (5) , 1010-1016
A Retrospective Comparison of Older and Younger Adults Undergoing Early Laparoscopic Cholecystectomy for Mild to Moderate Calculous Cholecystitis
Objectives: To compare the demographic characteristics and intra‐ and postoperative outcomes in elderly adults (≥75) with those of younger adults undergoing early (P < .001), higher serum creatinine (103 vs 74 μmol/L, P < .001), and more‐severe ACC (moderate ACC (62% vs 50%, P = .05), gangrenous cholecystitis (38% vs 15%, P = .001)) on preoperative imaging and confirmed intraoperatively. Ulcerated mucosa (76% vs 61%, P = .001) was significantly more frequent in the elderly group. Operative time, postoperative mortality, and postoperative infectious (18% vs 14%, P = .35) and noninfectious (9% vs 3%, P = .80) complications were similar between the two groups. Median length of stay (7.0 vs 5.0 days, P = .54) and readmission rate (15% vs 4%, P = .07) were not significantly higher in the elderly group. No significant difference was observed for the subgroup of participants aged 80 and older. Conclusion: In this randomized trial that included a selected sample of older adults, there was no difference in major outcomes between elderly adults and their younger counterparts after early cholecystectomy. The findings are limited because important geriatric outcomes such as delirium and functional decline were not examined.
- 6 May 2015
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 63 (5) , 1010-1016
A Retrospective Comparison of Older and Younger Adults Undergoing Early Laparoscopic Cholecystectomy for Mild to Moderate Calculous Cholecystitis
Objectives: To compare the demographic characteristics and intra‐ and postoperative outcomes in elderly adults (≥75) with those of younger adults undergoing early (P < .001), higher serum creatinine (103 vs 74 μmol/L, P < .001), and more‐severe ACC (moderate ACC (62% vs 50%, P = .05), gangrenous cholecystitis (38% vs 15%, P = .001)) on preoperative imaging and confirmed intraoperatively. Ulcerated mucosa (76% vs 61%, P = .001) was significantly more frequent in the elderly group. Operative time, postoperative mortality, and postoperative infectious (18% vs 14%, P = .35) and noninfectious (9% vs 3%, P = .80) complications were similar between the two groups. Median length of stay (7.0 vs 5.0 days, P = .54) and readmission rate (15% vs 4%, P = .07) were not significantly higher in the elderly group. No significant difference was observed for the subgroup of participants aged 80 and older. Conclusion: In this randomized trial that included a selected sample of older adults, there was no difference in major outcomes between elderly adults and their younger counterparts after early cholecystectomy. The findings are limited because important geriatric outcomes such as delirium and functional decline were not examined.
- 1 February 2015
- Published by Elsevier in Annales de Chirurgie Plastique Esthétique
- Vol. 60 (1) , 26-34
Complications des abdominoplasties : particularités des patients post-bariatriques au sein d’une série de 238 patients
- 1 February 2015
- Published by Elsevier in Annales de Chirurgie Plastique Esthétique
- Vol. 60 (1) , 26-34
Complications des abdominoplasties : particularités des patients post-bariatriques au sein d’une série de 238 patients
- Open Access
- 1 January 2015
- Published by Baishideng Publishing Group Inc. in World Journal of Hepatology
- Vol. 7 (13) , 1755-60
Surgical treatment of intra hepatic recurrence of hepatocellular carcinoma
Recurrence after hepatocellular carcinoma (HCC) is frequent. Currently, there are no recommendations on therapeutic strategy after recurrence of HCC. Whereas the 5 year-recurrence rate after resection of HCC is 100%, this drops to 15% after primary liver transplantation. Repeat hepatectomy and salvage liver transplantation (SLT) could be performed in selected patients to treat recurrent HCC and enable prolonged overall survival after treatment of recurrence. Other therapies such as local ablation, chemoembolization or sorafenib could be proposed to those patients unable to benefit from resection or SLT. A clear definition of the place of SLT and "prophylactic" liver transplantation is required. Indeed, identifying risks factors for recurrence at time of primary liver resection of HCC may help to avoid recurrence beyond Milan criteria and non-resectable situations. In this review, we summarize the recent data available in the literature on the feasibility and outcomes of repeat hepatectomy and SLT as treatment for recurrent HCC.
- 1 January 2015
- Published by Baishideng Publishing Group Inc. in World Journal of Hepatology
- Vol. 7 (13) , 1755-60
Open AccessSurgical treatment of intra hepatic recurrence of hepatocellular carcinoma
Recurrence after hepatocellular carcinoma (HCC) is frequent. Currently, there are no recommendations on therapeutic strategy after recurrence of HCC. Whereas the 5 year-recurrence rate after resection of HCC is 100%, this drops to 15% after primary liver transplantation. Repeat hepatectomy and salvage liver transplantation (SLT) could be performed in selected patients to treat recurrent HCC and enable prolonged overall survival after treatment of recurrence. Other therapies such as local ablation, chemoembolization or sorafenib could be proposed to those patients unable to benefit from resection or SLT. A clear definition of the place of SLT and "prophylactic" liver transplantation is required. Indeed, identifying risks factors for recurrence at time of primary liver resection of HCC may help to avoid recurrence beyond Milan criteria and non-resectable situations. In this review, we summarize the recent data available in the literature on the feasibility and outcomes of repeat hepatectomy and SLT as treatment for recurrent HCC.
- 1 January 2015
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 261 (1) , e28-e29
Predictive Factors for the Benefit of Perioperative FOLFOX for Resectable Liver Metastasis in Colorectal Cancer Patients (EORTC Intergroup Trial 40983)
- 1 January 2015
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 261 (1) , e28-e29
Predictive Factors for the Benefit of Perioperative FOLFOX for Resectable Liver Metastasis in Colorectal Cancer Patients (EORTC Intergroup Trial 40983)
- 1 October 2014
- Published by Elsevier in Journal de Chirurgie Viscérale
- Vol. 151 (4) , A35
Facteurs prédictifs de morbi mortalité chez les patients âgés de plus de 80 ans pris en charge en urgence en chirurgie digestive
- 1 October 2014
- Published by Elsevier in Journal de Chirurgie Viscérale
- Vol. 151 (4) , A35
Facteurs prédictifs de morbi mortalité chez les patients âgés de plus de 80 ans pris en charge en urgence en chirurgie digestive